Gynecologic Oncology

The Japanese Ministry of Health, Labour, and Welfare has approved the combination of pembrolizumab plus lenvatinib for use in patients with unresectable, advanced, or recurrent endometrial carcinoma that has progressed on chemotherapy.

Throughout 2021, investigators of several pivotal trials presented findings that may result in shifting standards for the treatment of patients across tumor types.

Closing out their discussion on the management of cervical cancer, panelists share their excitement for future evolutions in care.

Experts share their experience and thoughts on the use of tisotumab vedotin as the management of metastatic cervical cancer continues to evolve.

Image-guided intensity-modulated radiotherapy caused less toxicity compared with three-dimensional conformal radiation therapy with no difference in disease outcomes in patients with cervical cancer undergoing postoperative radiation therapy.

Bhavana Pothuri, MD, discusses the challenges of DNA polymerase epsilon mutation testing in endometrial cancer.

Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.

Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.

Retifanlimab demonstrated encouraging antitumor activity with favorable tolerability in patients with recurrent microsatellite instability–high or mismatch repair deficient endometrial cancer, according to data from the phase 1 POD1UM-101 trial.

Closing out his discussion on the treatment of cervical cancer, Robert L. Coleman, MD, FACOG, FACS, provides thoughts on the optimal sequencing of therapy and importance of clinical trials.

Robert L. Coleman, MD, FACOG, FACS, shares practical advice on managing toxicities while treating cervical cancer with the combination of balstilimab and zalifrelimab.

Expert insight on the combination of balstilimab, a PD-1 inhibitor, and zalifrelimab, a CTLA-4 inhibitor, in patients with recurrent or metastatic cervical cancer.

Focusing on novel immune checkpoint inhibitors, Robert L. Coleman, MD, FACOG, FACS, breaks down preclinical and clinical data that support use of balstilimab in patients with advanced cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, reviews the treatment landscape of cervical cancer and identifies recent approvals that have improved patient care.

The European Commission has granted an approval to the combination of pembrolizumab and lenvatinib for the treatment of patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior platinum-containing therapy in any setting and who are not eligible for curative surgery or radiation.

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

Panelists discuss the latest advances in targeting HER2-positive breast cancer, the rapidly evolving landscape of triple-negative breast cancer, the role of maintenance therapy in ovarian cancer, and recent updates in the treatment of patients with endometrial and cervical cancers.

Investigators identified potentially actionable germline variants in 10% of unselected women with newly diagnosed endometrial cancer, supporting the use of upfront multigene panel testing for all in the population.

Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.

An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.

AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.

Utilizing a multidisciplinary approach to care is critical in the field of ovarian cancer with the substantial advancements that have been made with systemic chemotherapeutic regimens, PARP inhibitors, maintenance therapy, and surgical interventions.

Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.

Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.

The addition of a short-term, flat dose of bevacizumab to pembrolizumab was found to enhance the response to anti–PD-1 therapy in the absence of chemotherapy for patients with platinum-resistant epithelial ovarian cancer.